Opinion|Videos|December 1, 2025
Ongoing Research to Watch in Advanced Gastric/GEJ Cancer
Author(s)Yelena Y. Janjigian, MD, Zev A. Wainberg, MD
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.
Advertisement
Episodes in this series
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, outline major ongoing research efforts aimed at improving outcomes for patients with advanced gastric and GEJ cancers. They emphasize the importance of continued evaluation of immunotherapy combinations, biomarker-directed approaches, and next-generation targeted therapies. Janjigian and Wainberg also highlight broader areas of investigation in gastrointestinal oncology that could shape future treatment paradigms.
Advertisement
Related to this article
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.
Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery
Ruxolitinib 1.5% cream outperformed placebo vehicle in reducing lesional skin involvement in patients with epidermal or superficially sclerotic cutaneous chronic GVHD.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
3
Talquetamab Demonstrates Preserved Activity in MonumenTAL-1–Ineligible Patients With Relapsed/Refractory Myeloma
4
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
5